美国在生物制药领域的卓越（英）

MAY America’s Greatness in the Biopharmaceutical Sector: Sustaining U.S. Leadership©2025 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced ortransmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, withoutexpress written consent of IQVIA and the IQVIA Institute.IntroductionThe U.S. biopharmaceuticals sector — the collection of companies that discover,develop, and commercialize therapeutics and medicines for patients in the U.S.and around the world — contributes to the U.S. economy, healthcare system,and society through its focus on innovation and technology, while concurrentlyreducing mortality and morbidity from illness. The sector has developed aneco-system that combines a multitude of scientific discovery platforms withrobust dissemination of information, intellectual property protection, a globaltalent pool, funding markets that provide liquidity, and a relatively transparentand responsive regulatory regime. This eco-system has delivered enormousvalue and has been a major net contributor to the U.S.; however, there areaspects of the current system that can be improved, and competition from otherparts of the world is increasing. Addressing these issues — while maintainingor increasing the strengths of the existing eco-system — can contribute to thebroader goals of enhancing America’s global leadership and at the same timeincrease the contribution of this critical strategic sector.This Perspective from the IQVIA Institute for HumanData Science is intended to contribute to the currentdiscussion around several Executive Orders and policyproposals being discussed or implemented by thecurrent U.S. Administration. It draws on recent researchby the IQVIA Institute and others to bring a balancedand objective view of how the goals of the administrationcan be best supported by a vital and sustainedbiopharmaceutical sector. This Perspective is producedas a public service without external funding or support.REFERENCING THIS REPORTPlease use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. America’s Greatness in the Biopharmaceutical Sector: Sustaining U.S. Leadership. May 2025.Available from www.iqviainstitute.org Find Out MoreIf you wish to receive future reports from the IQVIAInstitute for Human Data Science or join our mailing list,visit iqviainstitute.org.MURRAY AITKENExecutive DirectorIQVIA Institute for Human Data Science American companies have led theworld in biomedical discovery andclinical research, and bring substantialdirect and indirect economiccontributions to the U.S.Biopharmaceuticals are a strategic sector for the U.S.The U.S. biopharmaceutical sector contributes to the U.S.economy, healthcare system, and society in multiple ways:1. Biomedical research leadership•The U.S. has led the world in biomedical discoveryand clinical research, focused on discovering anddeveloping innovative treatments and cures forpatients globally•American companies have discovered, patented, andconducted clinical research to achieve regulatoryapproval for 46% of the 634 novel drugs approvedglobally over the past decade, twice the output of allcompanies headquartered in Europe1•Scientists in America have achieved leadership inunderstanding genetics and molecular biology,immunology, cancer immunotherapy, infectiousdiseases, and many other disease areas, anddeploying gene editing tools, immunotherapy,monoclonal antibodies, CAR T-cell therapies, and othermechanisms and modalities•The research leadership is underpinned by a uniquecombination of public funding for basic researchvia the National Institutes for Health, university-led translational science, technology transfers fromacademic institutions to private sector entrepreneurs,venture capital funding, and larger companypartnerships•Major global pharmaceutical companies — over halfof which are headquartered in the U.S. — invested$190 billion in research and development activitiesin 2024, an increase of 73% from the level five yearsago, and representing over 25% of net revenue2•The U.S. also has a regulatory agency andenvironment that is viewed as the gold standard bymany other agencies around the world, providingessential guidance and support to speed innovationsthat make medical products more effective, safer,and more affordable, thereby contributing to theadvancement of public health for all Americans2. Economic contributions•The direct and indirect economic contribution ofthe U.S. biopharmaceutical sector is estimated to be$1.65 trillion, including $800 billion in direct outputin 2022, and an additional $850 billion through itssuppliers and other sectors; this combined outputimpact represents 3.6% of all U.S. output•The sector is also responsible for direct and indirectemployment of 4.9 million Americans, includingmore than 1 million